

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 308 473 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
07.05.2003 Bulletin 2003/19

(51) Int Cl.7: **C08G 18/42, C08G 18/80,
A61L 27/00**

(21) Application number: **02080448.0**

(22) Date of filing: **04.06.1999**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IT LI LU NL PT
SE**

(30) Priority: **05.06.1998 EP 98201868**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
99939800.1 / 1 093 483

(71) Applicant: **Polyganics B.V.**
9713 GX Groningen (NL)

(72) Inventors:
• **Spaans, Coenraad Jan**
9712 KZ Groningen (NL)

- **Dekens, Folkert Gerhardus**
9727 CK Groningen (NL)
- **de Groot, Jacqueline Hermina**
9351 SR Leek (NL)
- **Pennings, Albert Johan**
3680 Maaseik (BE)

(74) Representative: **Prins, Adrianus Willem et al**
Vereenigde,
Nieuwe Parklaan 97
2587 BN Den Haag (NL)

Remarks:

This application was filed on 19 - 12 - 2002 as a
divisional application to the application mentioned
under INID code 62.

(54) **Biomedical polyurethane, its preparation and use**

(57) The invention is directed to a novel biomedical polyurethane based on diisocyanate linked polyester polymer and diol components, said diol component having a uniform block-length.

EP 1 308 473 A1

Description

[0001] The invention is directed to biomedical polyurethanes and the use thereof in various applications.

[0002] Biomedical polyurethanes (PUs) have been used for a wide range of applications. Examples include nerve guides, meniscal reconstruction materials, artificial skin and artificial veins.

[0003] For these applications, usually commercially available polyurethanes are used. These materials frequently exhibit good mechanical properties but an important disadvantage is that they contain aromatic diphenylmethane diisocyanate (MDI). MDI based polyurethanes are known to release carcinogenic and mutagenic products on degradation. Furthermore, they often show low resistance to tearing. A high resistance to tearing is important to prevent sutures from tearing out of a biomaterial. The development of new medical grade polyurethanes with good mechanical properties is therefore highly desirable.

[0004] Further an important aspect of the biomedical polyurethanes is the requirement that they can be processed into porous shaped bodies, e.g. as implants.

[0005] In the development of the novel materials of the invention, first porous 50/50 copoly(ϵ -caprolactone/L-lactide) materials were used for the reconstruction of meniscal lesions. They showed a very good adhesion to the meniscal tissue and, therefore, a good healing of the meniscal lesion. The mechanical properties of this copolymer resemble the mechanical properties of polyurethanes because of the high molecular weight and the presence of crystallisable L-lactide sequences. The polymer had, however, certain drawbacks. First, the degradation rate was somewhat too high. New meniscal tissue, the so called fibrocartilage, is formed after an induction time of 10 to 20 weeks.

[0006] Second, due to the very high molecular weight of the polymer a maximum concentration of 5% could be reached. This resulted in very low compression moduli of porous materials. For the ingrowth of fibrocartilage higher moduli were needed. Finally, the L-lactide crystals, which are still present after 8 years of in-vitro degradation, may induce an inflammatory reaction since cells cannot digest them unlike poly(ϵ -caprolactone) and polyglycolide crystals.

[0007] To avoid lactide crystallinity, an amorphous 50/50 copoly(ϵ -caprolactone/85,15 L,D-lactide) was used for the production of nerve guides. Due to the absence of crystals, however, this polymer showed swelling upon degradation. Therefore, the focus was put on the synthesis of ϵ -caprolactone and L-lactide based polyurethanes. The urethane hard segments crystals are likely to be small and susceptible to enzymatic degradation. In addition, by making an ϵ -caprolactone and L-lactide based PU the biocompatibility may be improved.

[0008] When the copolymer was simply chain extended with diisocyanates, the mechanical properties of the resulting polymer were poor due to the absence of a phase separated morphology. Phase separated morphologies can be reached when an isocyanate terminated polyol is chain extended with a diamine or diol resulting in a polyurethane urea and polyurethane respectively. However, the L-lactide and ϵ -caprolactone based prepolymer showed a deviant behavior with respect to chain extension using a diamine and diol. It appeared that the prepolymer was susceptible to aminolysis and transesterification unlike ϵ -caprolactone and glycolide/trimethylene carbonate prepolymers.

[0009] The invention is directed to novel biomedical polyurethanes, suitable for implants, not having the disadvantages discussed above.

[0010] Further it is an aspect of the invention to provide a novel intermediate for this polyurethane, as well as a novel way of producing the polyurethane.


[0011] In a first aspect the invention is directed to novel biomedical polyurethanes, based on diisocyanate linked polyester (co)polymer and diol components, said diol component having a uniform block-length.

[0012] According to a preferred embodiment, the polyurethane may be represented by the following formula:



wherein the B denote diisocyanate moieties, A denotes a polyester moiety, C denotes a diol moiety and n is the number of recurring units.

[0013] In a most preferred embodiment the polyurethane consists of repeating units of the following formula



wherein R_1 is an n-butylene moiety, D is a polyester moiety, E is an n-butylene diol, an n-hexylene diol or a diethylene glycol based moiety and n indicates the number of repeating units.

[0014] With respect to the above formulae it is to be noted that they represent the recurring units of the polyurethane. The endgroups are not represented thereby. The nature of the endgroups will vary according to the type of (co)polyester and diol, as well as with the production process.

[0015] Further preferred embodiments of the invention are indicated in the dependent claims and/or the list of features

under "Summary of the invention" hereinbelow.

[0016] The products of the present invention show a good balance between the properties necessary for use thereof in biomedical applications, such as good modulus, tensile strength and compression modulus. It has been found possible to process these materials into porous implants by salt-leaching and freeze-drying, resulting in a material having macropores in the range of 150 μm to 300 μm . The material can also be produced in situ in an extruder, even in combination with generating macropores in situ.

[0017] As has been indicated above, the conventional methods of producing polyurethanes may result in transesterification and aminolysis, with the consequence that the material has insufficiently balanced properties. More in particular the uniformity of block-length gets lost, resulting in loss of phase separation. The consequence thereof is that the mechanical properties deteriorate to a level below that which is acceptable for numerous biomedical applications.

[0018] An important feature of these polyurethanes is that they owe their good mechanical properties to the phase separated morphology. Because the soft segments (e. g. polyesters, polycarbonates or polyethers) are chemically incompatible with the hard segments (urethane, urea or amide moieties) phase separation occurs. The hard segments crystallize and form strong hydrogen bonds with other hard segments resulting into physical cross-links.

[0019] The behavior of these polyurethanes is in strong contrast with other polyurethanes often applied. A well-known example is polyurethanes in which 2 different, chemically incompatible, soft segments (e. g. polyesters and polyethers) are coupled by a diisocyanate. An example thereof is disclosed in US-A 4,284,506. In this case, also a certain extent of phase separation will occur, but these materials do not owe their mechanical properties to the ability of the urethane functionality to form hydrogen bonds but to the contribution of entanglements and phase separation between the different soft segments. The reason why the urethane functionalities can not contribute to the mechanical properties of the material is that the urethane moieties are too small to crystallize and form hydrogen bonds.

[0020] Polyurethanes with a micro-phase separated morphology frequently exhibit good mechanical properties and are generally easy to process due to the relatively low melting point.

[0021] Mechanical properties of polyurethane ureas are usually even better resulting from the increased crystallizability and hydrogen bonding ability of the urea moieties. The polymers, however, frequently have melting points that are close to the degradation temperature, leading to a small processing window.

[0022] The polymers of the present invention, contain long urethane-based hard segments of uniform size. This results into a system wherein the hard segments have increased crystallizability and hydrogen bonding ability compared to "classical" polyurethanes. The mechanical properties are comparable to those of polyurethane ureas. However, the melting point is still rather low which makes processing relatively easy.


[0023] It should be noted that the uniformity of the urethane-based hard segments is the crucial factor for the mechanical properties of the materials. The preferred method for the synthesis of these polyurethanes should therefore be the reaction of the diol component with an excess of diisocyanate followed by reaction with the macro-diol (e. g. polycaprolactone or copolymers of L-lactide and caprolactone). In this process, trans-esterification of the soft segment with the chain extender is avoided, resulting into hard segments of uniform size.

[0024] As has been indicated above, the polyurethane of the invention comprises in the most general form diisocyanate linked diol and polyester, more in particular linear random copolyester, components. The nature of the diol component is very important, especially with respect to the uniformity of the block-length. The diol and the (linear random co)polyester are connected to each other by diisocyanate, more in particular 1,4-butane diisocyanate.

[0025] The polyurethane of the present invention can be prepared by different processes. In a first process the diol component, i.e. the butanediol, hexanediol or diethylene glycol, or the reaction product of two molecules of the said diol with 1,4-butanediisocyanate (BDO-BDI-BDO), is reacted with an isocyanate terminated polyester, i.e. the reaction product of the random polyester with an excess of BDI (BDI-polyester-BDI). By selection of the reaction conditions (temperature, time, catalyst, and the like) the molecular weight of the polyurethane may be selected.

[0026] In the alternative the diol component is end-capped with the BDI and reacted with the random copolyester.

[0027] According to a further method it is possible to end-cap the polyester with the isocyanate endcapped diol component resulting (in the case of a dihydroxy terminated polyester) in a prepolymer of the following composition:



[0028] This prepolymer can subsequently be reacted with water to yield a polyurethane urea according to the invention. This process provides the possibility to generate porous materials in situ, for example by mixing the prepolymer with salt and water, and letting the material react for some time at a suitable temperature. After leaching the salt from the material a porous polyurethane urea has been obtained, whereby part of the pores are provided by the salt and part by the CO_2 generated in the reaction of the prepolymer with the water.

[0029] The reactions between the various components are carried out under the conditions known to be suitable for the preparation of polyurethanes.

[0030] These processes all result in a useful biomedical polyurethane, having the advantageous properties cited above.

[0031] It is to be noted that the use of an isocyanate endcapped diol has preference, especially in case the polyester component has the tendency to transesterify.

5 [0032] After the preparation of the base material it is possible to process it further, e.g. from a solution in an organic solvent such as dioxane, into shaped materials. For some applications it is useful to have a porous structure. This can be obtained by the method as described in De Groot et al, Use of biodegradable polymer implants in meniscus reconstruction, Colloid Polym. Sci., 1990, 268, 1073-1081. In case of the use of the polyurethane of the invention in meniscus reconstruction, it is useful to have porosities of 50 to 99 vol.%.

10 [0033] The diol component to be used in the present invention has to meet the requirement of uniform block-length. In practice this will mean that at least 90%, preferably at least 98% of the diol component molecules will have the same block-length. Suitable diol components can be based on 1,4-butanediol, 1,6-hexanediol or diethylene glycol. It is possible to use the diol as such, but it is also possible to use a reaction product of a diisocyanate (e.g. 1,4-butanediisocyanate) and two molecules of the diol (BDO-BDI-BDO). Optionally one may end-cap this reaction product with two
15 molecules of BDI, resulting in a five-block, that can be used in the reaction with the linear random copolyester.

[0034] The polyester to be used in accordance with the invention will preferably be linear, more in particular be a random copolyester, and will have reactive endgroups. These endgroups may be hydroxyl or carboxyl. It is preferred to have a dihydroxy terminated copolyester, but hydroxy-carboxyl or dicarboxyl terminated copolyesters can also be used. The nature of the endgroups is determined by the type of comonomers, the amounts thereof, the type of starter
20 (if used), and the reaction conditions. It is to be noted, that the molecular weight of the polyurethane in the present invention is not so crucial for obtaining the necessary mechanical properties, as is the case in the prior art. Accordingly, lower molecular weights often suffice.

[0035] Suitable monomers for the polyester are the cyclic monomers that can be polymerised under ring-opening polymerisation conditions. Examples are lactides, glycolides, trimethylene carbonate and/or ϵ -caprolacton. Preferred
25 are lactide (D, L, D-L, meso) and ϵ -caprolacton. More in particular a linear random copolyester having about equimolar amounts of ϵ -caprolacton and L-Lactide is preferred. Other possibilities include polyesters based on succinic acid and ethylene glycol or 1,4-butanediol, or on (co)polyesters of lactic acid. In case the polyester has to be linear, it can be prepared using a difunctional component (diol) as starter, but in case a three or higher functional polyol is used, star shaped polyesters may be obtained.

30 [0036] The conditions for preparing the polyesters are those known in the art.

[0037] The invention is now elucidated on the basis of the examples.

Experimental

35 Materials

[0038] L-lactide, ϵ -caprolactone were obtained from Hycail bv. (Noordhorn, The Netherlands) and used after standard purification. The catalyst stannous octoate (SnOct_2) was obtained from Sigma Corp. USA and used directly from the supplier. 1,4-Butane diisocyanate (DSM, Geleen, The Netherlands) was distilled under reduced nitrogen pressure;
40 1,4-butanediol (BDO, Acros Organics) from 4Å molecular sieves, dimethyl sulfoxide (DMSO, Acros Organics) from CaH_2 .

Prepolymer synthesis

45 [0039] For the 50/50 L-lactide and ϵ -caprolactone, 20 gram of L-lactide (0.14 mol) was mixed with 16 gram ϵ -caprolactone (0.14 mol) under nitrogen atmosphere. 1.70 gram butanediol (18.87 mmol) and 40 mg stannous octoate were added as initiator and catalyst respectively. The mixture was polymerized for 24 hours at 130°C. $^1\text{H-NMR}$ showed complete conversion.

50 Block synthesis

[0040] The isocyanate terminated urethane block (BDI/BDO/BDI) was prepared by reaction of butanediol with a six-fold excess of butanediisocyanate at 80°C without catalyst for 5 hours. The excess diisocyanate was removed by washing with dry hexane.

55 [0041] The hydroxyl terminated urethane block (BDO/BDI/BDO) was prepared by mixing butanediisocyanate with a six-fold excess of butanediol at 80°C without catalyst, for five hours. The excess butanediol was removed by washing with dry acetone.

Polymerization

[0042] The prepolymer (50/50 ϵ -caprolactone/L-lactide) or the diisocyanate end-capped prepolymer was dissolved in DMSO. The chain extender butanediol or block were dissolved in DMSO. The chain extender solution was added drop wise to the prepolymer solution under mechanical stirring. The total polymer concentration after chain extension was 5 w/w% in the case of butanediol, 30 w/w% in the case of the isocyanate terminated block and 50 w/w% for butanediol and the hydroxyl terminated block.

Characterization

[0043] Intrinsic viscosities were measured using a Ubbelohde viscometer.

[0044] Calorimeter studies were carried out with a Perkin Elmer DSC 7 calorimeter. The scanning rate was 10°C per minute.

¹H-NMR (200 MHz) was used to characterize the blocks.

[0045] Tear strength and hysteresis were determined.

Table 1

	Prepolymer	chain-extender
a	Isocyanate terminated prepolymer*	BDO
b	Prepolymer*	BDI/BDO/BDI
c	Isocyanate terminated prepolymer* *50/50 L-lactide/ ϵ -caprolactone 2000	BDO/BDI/BDO

[0046] When the butanediisocyanate terminated prepolymer was chain extended with a BDI-BDO-BDI block (table 1, b), a polymer with an intrinsic viscosity of 1.0 dL/g could be made. The DSC thermogram of the polymer is shown in figure 1. The mechanical properties of the products based on a-c (table 1) are presented in table 2.

Table 2

[η] (dL/g)	Modulus (MPa)	Tensile Strength (MPa)	Strain at break (%)	T _m (°C)	ΔH (J/g)	T _g (°C)	Permanent Deformation (%)
1.8	12	12	750	53	5.5	-9	13.5
1.0	60	23	640	50, 92	8.6, 4.6	-21	13.5
2.0	62	44	560	49, 112	2.3, 16	-5	10.0

[0047] These experiments show that the method b of table 1 provides products with better mechanical properties, than method a.

[0048] The role of the uniformity of the hard segments has also been demonstrated by the following example:

[0049] Polycaprolactone (M=2000) was end-capped with an excess of 1,4-butanediisocyanate. The excess of diisocyanate was removed by distillation. The resulting macro-diisocyanate was chain-extended with the BDO. BDI. BDO block. The resulting polyurethane had an intrinsic viscosity of 2.00 dL/g and a modulus of 70 MPa.

[0050] When polycaprolactone (M=2000) was chain-extended with a BDI. BDO. BDI. BDO. BDI block, a polyurethane of identical composition was obtained. However, in this case transesterification reactions of the chain-extender with the polycaprolactone soft segment were avoided. This resulted into a polymer with an intrinsic viscosity of 1.00 dL/g and a modulus of 105 MPa. The lower viscosity of the polymer can be explained by the lower reactivity of the BDI. BDO. BDI. BDO. BDI block compared to the BDO. BDI. BDO block. However, the modulus M has significantly increased. This is a result of the uniform hard segments. Hard segments of uniform size are more crystalline and thus more difficult to disrupt.

[0051] The absence of a melting endotherm at 60°C provides additional evidence that by this method trans esterification reactions were avoided.

Summary of the invention

[0052] The invention may be further summarized by the following features 1-15.

1. Biomedical polyurethane based on diisocyanate linked polyester polymer and diol components, said diol com-


ponent having a uniform block-length.

2. Biomedical polyurethane according to feature 1, having the following formula:



wherein the B denotes diisocyanate moieties, A denotes a polyester moiety, C denotes a diol moiety and n is the number of recurring units.

3. Biomedical polyurethane according to feature 1 or 2 consisting of repeating units of the following formula



wherein R_1 is an n-butylene moiety, D is a polyester moiety, E is an n-butylene diol, an n-hexylene diol or a diethylene glycol based moiety and n indicates the number of repeating units.

4. Polyurethane according to feature 1-3, wherein E is diol or an XYX reaction product of diol (X) and 1,4-butane-diisocyanate (Y).

5. Polyurethane according to feature 1-4, wherein the blocklength is the same for at least 90%, more in particular at least 98% of the diol units.

6. Polyurethane according to feature 1-5, wherein the polyester is based on a polyester prepared by ringopening polymerisation, preferably a random copolyester.

7. Polyurethane according to feature 6, wherein the random copolyester is a copolyester of lactide, glycolide, trimethylene carbonate and/or ϵ -caprolacton.

8. Polyurethane according to feature 1-6, wherein the polyester is based on lactic acid, succinic acid, ethylene glycol, 1,4-butanediol, 1,6-hexanediol and/or diethylene glycol.

9. Polyurethane according to feature 1-8, obtainable by a process comprising reacting the polyester and an isocyanate endcapped diol component, the ratio of isocyanate groups to polyester endgroups being at least two, followed by reacting the resulting prepolymer with water.

10. Polyurethane according to feature 7, based on a copolyester of lactide and ϵ -caprolacton containing 5 to 95, preferably 40-60 % of units of lactide and 5 to 95, preferably 40-60 % of units of ϵ -caprolacton, based on number.

11. 1,4-Butanediol, 1,6-hexane diol, or diethyleneglycol based diol component having a uniform blocklength, said component being an XYX reaction product of diol (X) and 1,4-butane-diisocyanate (Y).

12. Process for the preparation of a biomedical polyurethane according to feature 1-9 or 11, wherein the diol component is reacted with the reaction product of at least two moles of diisocyanate and the polyester.

13. Process for the preparation of a biomedical polyurethane according to feature 1-9 or 11, wherein the random copolymer is reacted with the reaction product of at least two moles of diisocyanate and the diol component.

14. Implants based on the biomedical polyurethanes according to feature 1-10, having a porosity of 50 to 99 vol.%. 16. Use of a polyurethane according to feature 1-10, as biodegradable polymer implant in meniscus reconstruction.

Claims

1. Biodegradable biomedical polyurethane having a phase separated morphology, comprising soft segments of polyester, polycarbonate and/or polyether components and polyurethane based hard segments, said hard segments containing a diol component having a uniform block length, wherein said blocklength is the same for at least 90% of said diol units and wherein the diol component on the one hand and the polyester, polycarbonate and/or polyether components on the other hand, have been linked by a diisocyanate, preferably an aliphatic diisocyanate.

2. Biomedical polyurethane according to claim 1, having urethane-based hard segments, obtainable by reaction of said diol component with an excess of diisocyanate followed by reaction with said soft segment component.


3. Biomedical polyurethane according to claim 1, having urethane-based hard segments, obtainable by reaction of said diol component with an isocyanate terminated soft segment component being the reaction product of the dihydroxy terminated soft segment component and at least two moles of diisocyanate.

4. Biomedical polyurethane according to any of the previous claims, having the following formula:



wherein A denotes said soft segment, B denotes said diisocyanate, C denotes said diol component and n is the number of recurring units.

- 5 5. Biomedical polyurethane according to any of the previous claims consisting of repeating units of the following formula



wherein R_1 is an n-butylene moiety; D is a polyester moiety; E is an n-butylene diol, an n-hexylene diol, a diethylene glycol based moiety or an YXY reaction product of diol (X) and 1,4-butane-diisocyanate (Y); and n indicates the number of repeating units.

6. Polyurethane according to any of the previous claims, wherein the blocklength is the same for at least 98% of said diol units.

- 20 7. Polyurethane according to any of the previous claims, wherein said soft segment is based on a polyester prepared by ringopening polymerisation, preferably a polycaprolacton.

8. Polyurethane according to claim 7, wherein the polyester is a random copolyester of lactide, glycolide, trimethylene carbonate and/or ϵ -caprolacton.

- 25 9. Polyurethane according to any of the previous claims, wherein the polyester is based on lactic acid, succinic acid, ethylene glycol, diethylene glycol, 1,4-butanediol, and/or 1,6-hexanediol.

- 30 10. Polyurethane according to any of the previous claims, obtainable by a process comprising reacting the polyester and an isocyanate endcapped diol component, the ratio of isocyanate groups to polyester endgroups being at least two, followed by reacting the resulting prepolymer with water.

- 35 11. Polyurethane according to claim 8, based on a copolyester of lactide and ϵ -caprolacton containing 5 to 95, preferably 40-60 % of units of lactide and 5 to 95, preferably 40-60 % of units of ϵ -caprolacton, based on number.

12. 1,4-Butanediol, 1,6-hexane diol, or diethyleneglycol based diol component having a uniform blocklength, said component being an YXY reaction product of diol (X) and 1,4-butane-diisocyanate (Y).

- 40 13. End-capped product, which is the reaction product of the YXY product of claim 12 and two molecules of diisocyanate.

14. 1,4-Butanediol, 1,6-hexane diol, or diethyleneglycol based component, said component being an YXY reaction product of diol (X) and 1,4-butane-diisocyanate (Y).

- 45 15. Implants based on the biomedical polyurethanes according to claim 1-11, having a porosity of 50 to 99 vol.%.

16. Material based on the biomedical polyurethanes according to claim 1-11 or according to claim 15, having macropores in the range of 150 - 300 μ m.

- 50 17. Use of a polyurethane according to claim 1-11 or material according to claim 15 or 16, as biodegradable polymer implant in meniscus reconstruction, nerve guides, artificial skin and artificial veins.




Figure 1. DSC thermogram of different ϵ -caprolactone and L-lactide based polyurethanes. a: Butanediisocyanate terminated copolymer prepolymer, chain extended with butanediol. b: Copolymer chain extended with butanediisocyanate end-capped butanediol block. c: 1,4-Butanediisocyanate terminated copolymer prepolymer, chain extended with butanediol end-capped 1,4-butanediisocyanate block.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 08 0448

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 4 284 506 A (CASE BARTON C ET AL) 18 August 1981 (1981-08-18) * column 3, line 44 - column 8, line 21 * * examples 11,12,34-36; table 1 * * claims 1,4 * ---	1-7,15, 17	C08G18/42 C08G18/80 A61L27/00
X	EP 0 295 055 A (YISSUM RES DEV CO) 14 December 1988 (1988-12-14) * page 2, line 4 - page 7, line 51 * * claims 1,18 * ---	1-7,15, 17	
X	GROOT DE J H ET AL: "USE OF POROUS POLYURETHANES FOR MENISCAL RECONSTRUCTION AND MENISCAL PROSTHESES" BIOMATERIALS, vol. 17, no. 2, 1 January 1996 (1996-01-01), pages 163-173, XP000551706 * figures 5,12 * ---	1-7,15, 17	
A	GROOT DE J H ET AL: "NEW BIOMEDICAL POLYURETHANE UREAS WITH HIGH TEAR STRENGTHS" POLYMER BULLETIN, vol. 38, no. 2, February 1997 (1997-02), pages 211-218, XP000678622 * the whole document * -----	1	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C08G A61L
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 March 2003	Examiner Bourgonje, A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 12 (P/M/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 08 0448

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-03-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4284506 A	18-08-1981	AU 6430580 A	02-07-1981
		BE 886862 A1	16-04-1981
		DE 3047832 A1	17-09-1981
		ES 8204749 A1	16-08-1982
		FR 2472392 A1	03-07-1981
		GB 2067580 A	30-07-1981
		IT 1212428 B	22-11-1989
		JP 56091757 A	24-07-1981
		NL 8006885 A	16-07-1981
EP 0295055 A	14-12-1988	IL 82834 A	05-11-1990
		CA 1329854 A1	24-05-1994
		EP 0295055 A2	14-12-1988
		JP 1195862 A	07-08-1989
		US 4826945 A	02-05-1989

EPO FORM 0448

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82